Clinical advantages of carbon-ion radiotherapy

Tsujii, Hirohiko; Kamada, Tadashi; Baba, Masayuki; Tsuji, Hiroshi; Kato, Hirotoshi; Kato, Shingo; Yamada, Shigeru; Yasuda, Shigeo; Yanagi, Takeshi; Kato, Hiroyuki; Hara, Ryusuke; Yamamoto, Naotaka; Mizoe, Jun‐etsu

doi:10.1088/1367-2630/10/7/075009

Cited by 92 publications

(77 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specific technique of CIRT used at NIRS has been described in detail in previous publications [1][2][3][4][5][6][7][8]. Briefly, patients were positioned in a customised cradle and immobilised with a low-temperature thermoplastic sheet.…”

Section: Carbon Ion Radiotherapy For Sacral Chordomamentioning

confidence: 99%

“…This level of approval is an intermediate step to being approved as a treatment under the national health insurance system in Japan. In the near future, the treatment of some cancers with CIRT will be covered by the national health insurance system [1,2]. In July 2009, the number of cases treated with CIRT exceeded 5000.…”

mentioning

confidence: 99%

“…The major cancers that have been treated with CIRT at NIRS are prostate cancer, bone and soft tissue sarcoma, head and neck cancer, recurring rectal cancer, lung cancer and hepatocellular carcinoma [1,2]. CIRT for bone and soft tissue sarcomas at NIRS was started in 1996 as a Phase I/II dose-escalation study for medically inoperable cases.…”

mentioning

confidence: 99%

“…CIRT for bone and soft tissue sarcomas at NIRS was started in 1996 as a Phase I/II dose-escalation study for medically inoperable cases. Details of the study have been described in previous articles [1,2,5]. Until February 2000, only 64 tumours in 57 patients were treated.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Carbon ion radiotherapy for sacral chordoma

Imai¹,

Kamada²,

Sugahara³

et al. 2011

BJR

View full text Add to dashboard Cite

ABSTRACT. The National Institute of Radiological Sciences in Chiba, Japan has offered carbon ion radiotherapy (CIRT) since 1994 using carbon ion beams generated by the heavy ion medical accelerator in Chiba (HIMAC). The total number of cases treated with the HIMAC exceeded 5000 in July 2009. Here, we present a retrospective analysis of CIRT for sacral chordoma. The study included 95 patients with medically unresectable sacral chordomas treated between 1996 and 2007. The median age of the patients was 66 years. Of all the patients, 84 had not been treated previously and 11 had a locally recurrent tumour following previous resection. The carbon ion dose ranged from 52.8 to 73.6 GyE (median 70.4 GyE) in a total of 16 fixed fractions over 4 weeks. The median clinical target volume was 370 cm 3 . The overall survival rate at 5 years for all 95 patients was 86%, and follow-up survival time was 42 months (range, 13-112 months). The 5-year local control rate was 88% and median time to local failure was 35 months (range, 13-60 months). Of the 95 patients, 91% remained ambulatory with or without a supportive device. Two patients experienced severe skin or soft tissue complications requiring skin grafts. 15 patients experienced severe sciatic nerve complications requiring continuing medication. CIRT appears effective and safe in the management of patients with sacral chordoma and offers a promising alternative to surgery.

show abstract

Section: Carbon Ion Radiotherapy For Sacral Chordomamentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Carbon ion radiotherapy for sacral chordoma

Imai¹,

Kamada²,

Sugahara³

et al. 2011

BJR

View full text Add to dashboard Cite

show abstract

“…Moreover, an evident enhancement of the Relative Biological Effectiveness (RBE) has been demonstrated in the case of carbon ions compared to protons, thus resulting in a more efficient treatment for most of the radio resistant tumors. [21][22][23][24] On the other hand, by using carbon ions, issues connected with projectile and target nuclear fragmentation can arise, thus leading to unwanted dose deposition beyond the Bragg peak caused by the lightest fragments. Moreover, nuclear fragmentation of the resulting mixed field, increases the uncertainty of the biological dose, which is ultimately released into the cancer tissues.…”

Section: Introductionmentioning

confidence: 99%

Prompt gamma ray diagnostics and enhanced hadron-therapy using neutron-free nuclear reactions

et al. 2016

View full text Add to dashboard Cite

We propose a series of simulations about the potential use of Boron isotopes to trigger neutron-free (aneutronic) nuclear reactions in cancer cells through the interaction with an incoming energetic proton beam, thus resulting in the emission of characteristic prompt gamma radiation (429 keV, 718 keV and 1435 keV). Furthermore assuming that the Boron isotopes are absorbed in cancer cells, the three alpha-particles produced in each p-11 B aneutronic nuclear fusion reactions can potentially result in the enhancement of the biological dose absorbed in the tumor region since these multi-MeV alpha-particles are stopped inside the single cancer cell, thus allowing to spare the surrounding tissues. Although a similar approach based on the use of 11 B nuclei has been proposed in [1], our work demonstrate, using Monte Carlo simulations, the crucial importance of the use of 10 B nuclei (in a solution containing also 11 B) for the generation of prompt gamma-rays, which can be applied to medical imaging. In fact, we demonstrate that the use of 10 B nuclei can enhance the intensity of the 718 keV gamma-ray peak more than 30 times compared to the solution containing only 11 B nuclei. A detailed explanation of the origin of the different prompt gamma-rays, as well as of their application as real-time diagnostics during a potential cancer treatment, is here discussed.

show abstract

Time‐resolved dosimetry with pencil‐beam scanning for quality assurance/quality control in particle therapy

Han

Furukawa

Hara

et al. 2021

J Applied Clin Med Phys

View full text Add to dashboard Cite

This study aimed to measure dose in a scanning carbon beam‐irradiation field with high sampling rate that is sufficient for identifying spots and verifying the characteristics of the scanning beam that cannot generally be derived from the dose. To identify the spot, which is the smallest control unit of beam information during irradiation, effecting measurements with a sampling time of 10 μs or shorter is necessary. The provided dose within a specific time is referred to as time‐resolved dose (TRD). We designed a circuit for time‐resolved dosimetry using a fast‐data acquisition unit (SL1000, Yokogawa Electric Co.), which can measure 100 000 samples per second. Moreover, we used converters to enable a connection between an ionization chamber (IC) and the SL1000. TRD was measured successfully using point irradiation and two‐dimensional irradiation patterns in a scanned carbon beam. Based on the moving time of the spot obtained from the position monitor, the dose delivered to the IC from each spot position (spot dose) was interpreted. The spot dose, displacement of the chamber from the beam's center axis, and beam size were derived using TRD and position monitor outputs, which were measured concurrent with TRD. Spot dose up to a radius of 8 mm area from the IC's center were observed. Using the spot‐dose equations and simulation, we show that the spot dose of each position varies depending on the beam size and displacement of the IC's center from the beam's center axis. We devise an interpretation method for the characteristics that may apply to quality assurance, such as the verification of the trend for the beam axis and isocenter to coincide, as well as beam‐size verification.

show abstract

Clinical advantages of carbon-ion radiotherapy

Cited by 92 publications

References 27 publications

Carbon ion radiotherapy for sacral chordoma

Carbon ion radiotherapy for sacral chordoma

Prompt gamma ray diagnostics and enhanced hadron-therapy using neutron-free nuclear reactions

Time‐resolved dosimetry with pencil‐beam scanning for quality assurance/quality control in particle therapy

Contact Info

Product

Resources

About